|
|
|
|
| LEADER |
05082nmm a2200289 u 4500 |
| 001 |
EB000634867 |
| 003 |
EBX01000000000000000487949 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781592593859
|
| 100 |
1 |
|
|a Wu, Alan H. B.
|e [editor]
|
| 245 |
0 |
0 |
|a Cardiac Markers
|h Elektronische Ressource
|c edited by Alan H. B. Wu
|
| 250 |
|
|
|a 2nd ed. 2003
|
| 260 |
|
|
|a Totowa, NJ
|b Humana Press
|c 2003, 2003
|
| 300 |
|
|
|a XVII, 467 p
|b online resource
|
| 505 |
0 |
|
|a 11 Interferences in Immunoassays for Cardiac Troponin -- 12 Cardiac Marker Measurement by Point-of-Care Testing -- 13 Standardization of Cardiac Markers -- 14 Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers -- IV. Early Cardiac Markers of Myocardial Ischemia and Risk Stratification -- 15 Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes -- 16 Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin -- 17 C-Reactive Protein for Primary Risk Assessment -- 18 Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes -- 19 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement -- 20 Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification --
|
| 505 |
0 |
|
|a I. Cardiac Markers in Clinical Practice -- 1 Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols -- 2 Management of Acute Coronary Syndromes -- 3 Evolution of Cardiac Markers in Clinical Trials -- 4 Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise -- 5 The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents -- 6 The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery -- II. Clinical Use for Cardiac Troponins -- 7 Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications -- 8 Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients -- 9 Cardiac-Specific Troponins Beyond Ischemic Heart Disease -- III. Analytical Issues for Cardiac Markers -- 10 Antibody Selection Strategies in Cardiac Troponin Assays --
|
| 505 |
0 |
|
|a 21 Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease -- V. Cardiac Markers of Congestive Heart Failure -- 22 Pathophysiology of Heart Failure -- 23 B-Type Natriuretic Peptide: Biochemistry and Measurement -- 24 B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure -- 25 Monitoring Efficacy of Treatment with Brain Natriuretic Peptide -- 26 N-Terminal Pro-B-Type Natriuretic Peptide -- VI. Role of Infectious Diseases and Genetics in Heart Disease -- 27 Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae -- 28 Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics
|
| 653 |
|
|
|a Pathology
|
| 653 |
|
|
|a Pathology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Pathology and Laboratory Medicine
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-59259-385-9?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.07
|
| 520 |
|
|
|a In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. The many new and updated chapters introduce new ischemic markers such as CRP, fatty acid binding protein, ischemia modified albumin, oxidized LDL, whole blood choline, and genetic polymorphisms that portend high risk for cardiovascular disease. The authors address analytical issues, assay development, cutoff concentrations, antibody selection schemes, point-of-care testing, in situ degradation of cardiac troponin, and updated clinical trials. They also discuss the emerging infectious disease etiology of heart disease, as well as the role of troponin in such non-ischemic diseases as renal failure, cardiac surgery, sepsis, myocarditis, and chemotherapeutic drug monitoring. Comprehensive and cutting-edge, Cardiac Markers, Second Edition not only offers physicians a complete guide to the use of cardiac markers in clinical practice, but also provides clinical laboratorians a close-up view of the new markers now becoming standard
|